Tewane Pharma
ActiveSummary
Tewane Pharma has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €101,856 and a net result of €41,836. Equity is growing by about 49% per year across the filed financial years. Its solvency ranks better than 57% of 615 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
01-04
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2021 to 2025net €41,836 ▲27.7%
Operating result €57,451, net result €41,836, both a record.
31-12
Financial
Equity above €100,000equity €101,856 ▲30.4%
A profit in every financial year since 2021 builds equity to €101,856.
30-05
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
26-06
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
01-07
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
22-07
NBB filing
Annual accounts filed
financial year 2021 · full format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.